Table 2 Patients’ characteristics according to Ki67 groups
Patients’ characteristics | Patients (%) | p-value | ||
|---|---|---|---|---|
Ki67 < 6 % [N = 171] | 6 % < Ki67 ≤ 21 % [N = 177] | Ki67 > 21 % [N = 19] | ||
Menopausal status | ||||
Premenopausal | 50 (29.2) | 47 (26.6) | 9 (47.4) | 0.16 |
Postmenopausal | 121 (70.8) | 130 (73.4) | 10 (52.6) | |
Performance status (ECOG) | 0.35 | |||
0 | 163 (95.3) | 162 (91.5) | 18 (94.7) | |
1–2 | 8 (4.7) | 15 (8.5) | 1 (5.3) | |
Type of surgery | ||||
Conservative surgery | 120 (70.2) | 113 (63.8) | 10 (52.6) | 0.20 |
Mastectomy | 51 (29.8) | 64 (36.2) | 9 (47.4) | |
Sentinel lymph-node biopsy | ||||
No | 92 (53.8) | 105 (59.3) | 14 (73.7) | 0.20 |
Yes | 79 (46.2) | 72 (40.7) | 5 (26.3) | |
Histological subtype | ||||
Pure lobular | 119 (69.6) | 129 (72.9) | 12 (63.2) | 0.72 |
Ductal-lobular | 48 (28.1) | 43 (24.3) | 7 (36.8) | |
Others | 4 (2.3) | 5 (2.8) | 0 (0) | |
T Descriptor according to TNM [7° Edition] | ||||
1 | 115 (67.3) | 93 (52.5) | 6 (31.5) | 0.01 |
2 | 43 (25.1) | 60 (33.9) | 11 (57.9) | |
3 | 11 (6.4) | 17 (9.6) | 1 (5.3) | |
4 | 2 (1.2) | 7 (4.0) | 1 (5.3) | |
Lymph-nodes status | ||||
Negative | 111 (64.9) | 92 (52.0) | 10 (52.6) | 0.06 |
Positive | 56 (32.7) | 74 (41.7) | 9 (47.4) | |
Unknown | 4 (2.3) | 11 (6.2) | 0 (0) | |
Estrogen receptor status | ||||
Negative | 6 (3.5) | 3 (1.7) | 2 (10.5) | 0.29 |
Positive | 164 (95.9) | 173 (97.7) | 17 (89.5) | |
Unknown | 1 (0.6) | 1 (0.6) | 0 (0) | |
Progesterone receptor status | ||||
Negative | 20 (11.7) | 14 (7.9) | 5 (26.3) | 0.14 |
Positive | 144 (84.2) | 157 (88.7) | 13 (68.4) | |
Unknown | 7 (4.1) | 6 (3.4) | 1 (5.3) | |
HER2 status | ||||
Negative | 124 (72.5) | 118 (66.7) | 11 (57.8) | 0.01 |
Positive | 4 (2.3) | 12 (6.8) | 4 (21.1) | |
Unknown | 43 (25.1) | 47 (26.6) | 4 (21.1) | |
Histological grade | ||||
1 | 47 (27.5) | 20 (11.3) | 0 (0) | <0.0001 |
2 | 57 (33.3) | 87 (49.2) | 9 (47.4) | |
3 | 15 (8.8) | 33 (18.6) | 6 (31.6) | |
Unknown | 52 (30.4) | 37 (20.9) | 4 (21.1) | |
Vascular invasion | ||||
Absent | 105 (61.4) | 102 (57.6) | 3 (15.8) | <0.0001 |
Present | 26 (15.2) | 45 (25.4) | 10 (52.6) | |
Unknown | 40 (23.4) | 30 (16.9) | 6 (31.6) | |
Multifocality | ||||
Absent | 131 (76.6) | 137 (77.4) | 16 (84.2) | 0.48 |
Present | 38 (22.2) | 38 (21.5) | 2 (10.5) | |
Unknown | 2 (1.2) | 2 (1.1) | 1 (5.3) | |
Adjuvant hormonotherapy | ||||
No | 20 (11.7) | 12 (6.8) | 5 (26.3) | 0.02 |
Yes | 151 (88.3) | 165 (93.2) | 14 (73.7) | |
Adjuvant chemotherapy | ||||
No | 111 (64.9) | 102 (57.6) | 1 (5.3) | <0.0001 |
Yes | 60 (34.1) | 75 (42.4) | 18 (94.7) | |
Adjuvant radiotherapy | ||||
No | 48 (28.1) | 54 (30.5) | 8 (42.1) | 0.48 |
Yes | 118 (69.0) | 114 (64.4) | 11 (57.9) | |
Unknown | 5 (2.9) | 9 (5.1) | 0 (0) | |